
FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.
Read MoreChester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration has approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.
Read MoreWASHINGTON, D.C. — This week, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for positron emission tomography (PET) imaging of prostate-specific …
Read MoreWAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic hyperplasia (BPH) worldwide.
Read MoreWAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that data from three studies of the UroLift® System were presented at the European Association of Urology (EAU) 2020 virtual congress, underscoring the …
Read More